HK1163526A1 - A medicament for treating schizophrenia comprising cilostazol - Google Patents

A medicament for treating schizophrenia comprising cilostazol

Info

Publication number
HK1163526A1
HK1163526A1 HK12104148.9A HK12104148A HK1163526A1 HK 1163526 A1 HK1163526 A1 HK 1163526A1 HK 12104148 A HK12104148 A HK 12104148A HK 1163526 A1 HK1163526 A1 HK 1163526A1
Authority
HK
Hong Kong
Prior art keywords
medicament
cilostazol
treating schizophrenia
schizophrenia
treating
Prior art date
Application number
HK12104148.9A
Other languages
English (en)
Inventor
Kenji Hashimoto
Masaomi Iyo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1163526A1 publication Critical patent/HK1163526A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12104148.9A 2007-03-30 2012-04-26 A medicament for treating schizophrenia comprising cilostazol HK1163526A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007092596 2007-03-30

Publications (1)

Publication Number Publication Date
HK1163526A1 true HK1163526A1 (en) 2012-09-14

Family

ID=39521659

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12104148.9A HK1163526A1 (en) 2007-03-30 2012-04-26 A medicament for treating schizophrenia comprising cilostazol

Country Status (11)

Country Link
US (1) US8431606B2 (de)
EP (1) EP2131838B1 (de)
JP (1) JP5299949B2 (de)
KR (1) KR101442295B1 (de)
CN (2) CN101677998B (de)
AR (1) AR065855A1 (de)
CA (1) CA2682347C (de)
ES (1) ES2393816T3 (de)
HK (1) HK1163526A1 (de)
TW (1) TW200848041A (de)
WO (1) WO2008123592A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012014993A1 (ja) * 2010-07-29 2013-09-12 国立大学法人 千葉大学 翻訳開始因子または翻訳伸長因子の増加剤、およびその医薬用途
AU2018367733B2 (en) * 2017-11-14 2024-06-20 Sk Biopharmaceuticals Co., Ltd. Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
TW202140039A (zh) * 2020-02-25 2021-11-01 日商大塚製藥股份有限公司 地西他濱及西屈嘧啶(cedazuridine)組合之固體口服劑型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3845059B2 (ja) 2000-08-14 2006-11-15 テバ ファーマシューティカル インダストリーズ リミティド シロスタゾールの製造方法
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
CN1222652C (zh) * 2002-05-31 2005-10-12 乐金电子(天津)电器有限公司 具有减震装置的洗衣机
TWI323660B (en) 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
CN1241566C (zh) * 2004-03-15 2006-02-15 深圳海王药业有限公司 西洛他唑固体分散体及其片剂制备方法
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition

Also Published As

Publication number Publication date
CN101677998B (zh) 2012-05-09
KR101442295B1 (ko) 2014-09-22
CN101677998A (zh) 2010-03-24
US8431606B2 (en) 2013-04-30
KR20090126315A (ko) 2009-12-08
EP2131838A1 (de) 2009-12-16
TW200848041A (en) 2008-12-16
WO2008123592A1 (en) 2008-10-16
CN102349907A (zh) 2012-02-15
AR065855A1 (es) 2009-07-08
JP5299949B2 (ja) 2013-09-25
US20100152247A1 (en) 2010-06-17
ES2393816T3 (es) 2012-12-28
EP2131838B1 (de) 2012-10-17
CA2682347C (en) 2014-07-15
CN102349907B (zh) 2013-06-05
JP2008273953A (ja) 2008-11-13
CA2682347A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX2020008616A (es) Rocio de fentanilo sublingual.
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
IN2012DN01233A (de)
WO2010111640A3 (en) Anti-influenza formulations and methods
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
TW200731974A (en) Transdermal system for verenicline
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX353024B (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
WO2011005052A8 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
PL2196206T3 (pl) Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
ZA200904346B (en) Synergistic active ingredient combination
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
MX2010001303A (es) Compuestos terapeuticos.
HK1163526A1 (en) A medicament for treating schizophrenia comprising cilostazol
MX2013008269A (es) Composicion farmaceutica que comprende derivados de piridona.
EP2269996A4 (de) Eine benzo[a]phenoxanthinverbindung als wirkstoff enthaltende medizinische zusammensetzung zur prävention oder behandlung von durch protozon verursachten krankheiten

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170328